Skip to main content
SpringerLink
Log in

Chronic Kidney Disease and Albuminuria in Arterial Hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Chronic kidney disease is a major public health problem worldwide: it is estimated that in the general population, 1 person in 10 has some degree of renal damage. Adequate blood pressure control represents the mainstay of treatment, to delay deterioration of renal function and prevent cardiovascular complications. Current evidence supports a target blood pressure value of 130/80 mm Hg or less (ie, <125/75 mm Hg) when proteinuria exceeds 1 g/L. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers represent the treatment of choice, especially in the presence of proteinuria. More complete blockade of the renin-angiotensin-aldosterone system (RAAS) has been advocated, using a combination of multiple RAAS blocker drugs or supramaximal doses to maximize renal protection. Achieving recommended blood pressure target values usually requires the use of multiple antihypertensive drugs, including diuretics and calcium channel blockers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008, 8:117.

    Article  PubMed  Google Scholar 

  2. Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038–2047.

    Article  CAS  PubMed  Google Scholar 

  3. Keith DS, Nichols GA, Gullion CM, et al.: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659–663.

    Article  PubMed  Google Scholar 

  4. Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296–1305.

    Article  CAS  PubMed  Google Scholar 

  5. Astor BC, Hallan SI, Miller ER 3rd, et al.: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008, 167:1226–1234.

    Article  PubMed  Google Scholar 

  6. United States Renal Data System, USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.

  7. Hsu CY, McCulloch CE, Darbinian J, et al.: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923–928.

    Article  PubMed  Google Scholar 

  8. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1–S266.

    Google Scholar 

  9. Mancia G, De Backer G, Dominiczak A, et al.; ESH-ESC Task Force on the Management of Arterial Hypertension: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25:1751–1762.

    Article  CAS  PubMed  Google Scholar 

  10. Plantinga LC, Miller ER 3rd, Stevens LA, et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006. Hypertension 2009, 54:47–56.

    Article  CAS  PubMed  Google Scholar 

  11. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.

    CAS  PubMed  Google Scholar 

  12. Brantsma AH, Bakker SJ, Hillege HL, et al.; PREVEND Study Group: Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008, 23:3851–3858.

    Article  CAS  PubMed  Google Scholar 

  13. Iseki K, Kinjo K, Iseki C, Takishita S: Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004, 44:806–814.

    CAS  PubMed  Google Scholar 

  14. de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.

    Article  PubMed  Google Scholar 

  15. de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921–927.

    Article  PubMed  Google Scholar 

  16. Eijkelkamp WB, Zhang Z, Remuzzi G, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540–1546.

    Article  CAS  PubMed  Google Scholar 

  17. Atkins RC, Briganti EM, Lewis JB, et al.: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005, 45:281–287.

    Article  PubMed  Google Scholar 

  18. Gaede P, Tarnow L, Vedel P, et al.: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004, 19:2784–2788.

    Article  PubMed  Google Scholar 

  19. Siragy HM, Carey RM: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010, 31:541–550.

    Article  CAS  PubMed  Google Scholar 

  20. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, et al.; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  CAS  PubMed  Google Scholar 

  21. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  CAS  PubMed  Google Scholar 

  22. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14:1738–1747.

    Article  CAS  PubMed  Google Scholar 

  23. Fyhrquist F, Saijonmaa O: Renin-angiotensin system revisited. J Intern Med 2008, 264:224–236.

    CAS  Google Scholar 

  24. Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during longterm angiotensin II suppression. J Endocrinol 1981, 91:457–465.

    Article  CAS  PubMed  Google Scholar 

  25. • Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48. This meta-analysis shows no difference between ACE inhibitors and ARBs in reducing urinary protein excretion. Proteinuria reduction is greater with dual RAAS blockade than with single-drug therapy.

    PubMed  Google Scholar 

  26. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.

    Article  CAS  PubMed  Google Scholar 

  27. The Editors of The Lancet: Retraction—Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. The Lancet 2009, 374:1226.

  28. • Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553. Renal data from the ONTARGET study demonstrated no renal benefit from dual RAAS inhibitors

    Article  CAS  PubMed  Google Scholar 

  29. Fried LF, Duckworth W, Zhang JH, et al.; VA NEPHRON-D Investigators: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361–368.

    Article  CAS  PubMed  Google Scholar 

  30. Wang CT, Zou LX, Navar LG: Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats. J Am Soc Nephrol 1997, 8:535–542.

    CAS  PubMed  Google Scholar 

  31. Rakugi H, Wang DS, Dzau VJ, Pratt RE: Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994, 90:449–455.

    CAS  PubMed  Google Scholar 

  32. Wagner J, Gehlen F, Ciechanowicz A, Ritz E: Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999, 10:545–551.

    CAS  PubMed  Google Scholar 

  33. Schmieder RE, Klingbeil AU, Fleischmann EH, et al.: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16:3038–3045.

    Article  CAS  PubMed  Google Scholar 

  34. Rossing K, Schjoedt KJ, Jensen BR, et al.: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190–1198.

    Article  CAS  PubMed  Google Scholar 

  35. Hollenberg NK, Parving HH, Viberti G, et al.: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007, 25:1921–1926.

    Article  CAS  PubMed  Google Scholar 

  36. •• Burgess E, Muirhead N, Rene de Cotret P, et al.; SMART (Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009, 20:893–900. Supramaximal doses of candesartan provide a greater reduction in proteinuria than conventional doses (ie, 16 mg/d) regardless of blood pressure reduction.

    Article  CAS  PubMed  Google Scholar 

  37. Hou FF, Xie D, Zhang X, et al.: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889–1898.

    Article  CAS  PubMed  Google Scholar 

  38. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet 2006, 368:1449–1456.

    Article  CAS  PubMed  Google Scholar 

  39. •• Parving HH, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446. This study was the first demonstration of greater proteinuria reduction with the novel direct renin blocker, aliskiren, in addition to an ARB in patients with hypertension and diabetic nephropathy.

    Article  CAS  PubMed  Google Scholar 

  40. Parving HH, Brenner BM, McMurray JJ, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663–1671.

    Article  CAS  PubMed  Google Scholar 

  41. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:542–551.

    Article  CAS  PubMed  Google Scholar 

  42. Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.

    Article  CAS  PubMed  Google Scholar 

  43. de Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883–892.

    Article  PubMed  Google Scholar 

  44. Bilous R, Chaturvedi N, Sjølie AK, et al.: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151:11–20.

    PubMed  Google Scholar 

  45. Haller H, Viberti GC, Mimran A, et al.: Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006, 24:403–408.

    Article  CAS  PubMed  Google Scholar 

  46. Sarafidis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007, 49:12–26.

    Article  CAS  PubMed  Google Scholar 

  47. • Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173–1181. This recent analysis of the ACCOMPLISH trial showed that antihypertensive combination therapy with ACE inhibitors plus calcium channel blockers is more effective than treatment with ACE inhibitors and diuretics for slowing progression of CKD.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Cardionephrology and Department of Internal Medicine, University of Genoa, Azienda Ospedaliera Universitaria San Martino, Viale Benedetto XV, 6–16132, Genoa, Italy

    Giovanna Leoncini, Francesca Viazzi & Roberto Pontremoli

Authors
  1. Giovanna Leoncini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Viazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Pontremoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Pontremoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leoncini, G., Viazzi, F. & Pontremoli, R. Chronic Kidney Disease and Albuminuria in Arterial Hypertension. Curr Hypertens Rep 12, 335–341 (2010). https://doi.org/10.1007/s11906-010-0141-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-010-0141-3

Keywords

Search

Navigation